Pharmaceuticals, Biotechnology and Life Sciences
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Today,…
FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation…
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based…
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model…
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental…
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) — The attached notifications relate to the vesting of earnout shares and associated…